Earnings Call Summary | GETINGE AB(GNGBF.US) Q2 2024 Earnings Conference
Earnings Call Summary | GETINGE AB(GNGBF.US) Q2 2024 Earnings Conference
Gross profit increased by SEK837 million to SEK4,151 million, with adjusted gross margin improving across all business areas.The following is a summary of the Getinge AB (GNGBF) Q2 2024 Earnings Call Transcript:
以下爲Getinge Ab(GNGBF)2024財年第二季度業績會摘要：
Financial Performance:
金融業績：
Getinge reported a 15.7% increase in net sales and 14.4% growth in order intake in Q2 2024.
Adjusted EBITDA margin improved by 4.9 percentage points year-on-year.
Gross profit increased by SEK837 million to SEK4,151 million, with adjusted gross margin improving across all business areas.
Getinge報告2024年第二季度淨銷售額增長15.7%，訂單收入增長14.4%。
調整後的EBITDA邊際率同比提高4.9個百分點。
毛利潤增加了8369百萬瑞典克朗至41510百萬瑞典克朗，調整後各業務領域毛利率均有所提高。
Business Progress:
業務進展：
Launched Poladus 150, an advanced low-temperature sterilizer, and received 510(k) clearance and EU MDR approval for new products.
Presented an updated earnings per share target with an average growth of over 12% for 2024-2028 during the Capital Market Update.
Advanced the quality improvement for products like Cardiosave and Cardiohelp and made progress towards sustainable productivity improvements.
推出了先進的低溫滅菌器Poladus 150，並獲得了新產品的510(k)和歐盟MDR批准。
在資本市場更新中，提出了更新後的每股收益目標，2024-2028年的平均增長率超過12%。
推進Cardiosave和Cardiohelp等產品的質量改進，並取得可持續生產力改進方面的進展。
Opportunities:
機會：
The company continues to see good market opportunities in Asia Pacific, expecting strong demand for healthcare.
Recent acquisitions are expected to contribute to 3-5 percentage points of growth, complemented by 2-5% expected organic net sales growth.
公司在亞太地區仍看到良好的市場機會，預計醫療保健需求強勁。
最近的收購預計將爲增長貢獻3-5個百分點，再加上2-5%的有機淨銷售增長。
Risks:
風險：
Quality-related challenges in Acute Care Therapies remain a priority.
Regulatory hurdles with pending CE mark approvals for new ECMO packaging.
急性護理治療方面的質量相關挑戰仍然是重點。
新ECMO包裝的CE標準批准存在監管障礙。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由AI生成。文章內容的準確性無法完全保證。有關更全面的詳細信息，請參閱IR網站。本文只是爲投資者提供參考，沒有任何指導或推薦建議。
